A global animal health company says a vaccine for African swine fever could be developed and distributed before 2025. Tim Bettington is Executive Vice President and President, U.S. Operations and Global Customer Experience with Zoetis. “It could take up to three more years to develop an active solution,” Bettington says. “Some of it will depend on if there will be emergency use vaccines available or not. Bettington says it’s likely FDA and other agencies would grant emergency use authorization. “I would say based on recent precedents that would be the case so as long as the government is very active and willing to work with companies to do so
The Department of Agriculture through the Bureau of Animal Industry (DA-BAI) — in collaboration with a US vaccine company, and Zoetiz, a global animal health company — has started initial vaccine trials in areas previously affected by the dreaded African Swine Fever (ASF). Agriculture Secretary William Dar said the ASF vaccine trials started on April 23, 2021, with 10 commercial swine farms participating. “The vaccine trials complement our ongoing ‘Bantay ASF sa Barangay’ program. We consider it as the proverbial ‘light at the end of the tunnel’ that would free us from this dark episode that adversely affected our swine industry, and pork supply and prices,” Secretary Dar said.
“Once proven effective, the ASF vaccine will serve as a potent tool, complementing our joint efforts with the LGUs, private sector, and hog raisers to effectively control, contain and manage the spread of the ASF, thus paving way for the industry’s faster recovery,” the DA chief added. The ASF vaccine trials will be conducted and monitored by the DA-BAI personnel and veterinarians for 84 days, in line with the current protocols set by the government technical working group, the vaccine manufacturer and Zoetis Philippines, Inc. Zoetis is the major collaborator of the experimental new vaccine for ASF, which has prevented the virus from killing pigs in an early trial in other countries. “We are now coordinating with the provincial veterinarians on the conduct of the vaccine trials to ensure successful implementation. Likewise, our BAI veterinarians have already undergone orientation and are ready for deployment.
Features of African Swine Fever Vaccine Zoetis
A new vaccine has been launched in Europe for pigs that will help tackle the ever-mutating porcine circovirus type 2 (PCV2). Over the past five to 10 years, the European swine industry has seen a significant dominance shift in its PCV2 strains from PCV2a to PCV2b and PCV2d now being dominant.
CircoMax Myco is the first vaccine registered in Europe that includes two genotypes of PCV2 – PCV2a and PCV2b – combined with a pure Mycoplasma hyopneumoniae (M. hyo) antigen. Because of this, CircoMax Myco offers broader antigenic coverage and the longest combined protection for PCV2 and M. hyo. Its ready-to-use formulation is administered as a single 2 ml dose intramuscularly in piglets from three weeks of age and provides at least 23 weeks duration of immunity against both PCV2 and M. hyo. The PCV2 protection has been demonstrated to provide coverage against PCV2a, PCV2b and PCV2d.
Benefits of African Swine Fever Vaccine Zoetis
Alongside protection for both PCV2a, PCV2b and PCV2d, CircoMax Myco includes Zoetis’ trusted Mycoplasma hyopneumoniae antigen, which is a pure, cell-free M. hyo antigen for targeted immune response. On its own, M. hyo can be a very costly respiratory disease and is a core pathogen in porcine respiratory disease complex (PRDC).
The vaccine is also formulated with the antigen MetaStim® which provides a robust cell-mediated immune response. It’s shown to be safe in field trials at varying doses with minimal injection site reactions and minimal post-vaccination depression in piglets. The vaccine also contains no mineral oil, reducing human safety issues compared to some competitors. CircoMax Myco is all about staying ahead of disease threats – an evolving PCV2 virus, subclinical infections, recombinations,” said Hancox. “With this vaccine’s broader antigen content, there’s better opportunity to stay one step ahead of an ever-changing PCV2 virus in the future.
Prices of African Swine Fever Vaccine Zoetis
$25.95 – $54.75